Stents Market Size, Share & Trends Analysis Report By Product (Vascular, Non-vascular), By Material (Metallic, Non-metallic), By End-use (Hospitals, Ambulatory Care Centers, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030

Stents Market Size, Share & Trends Analysis Report By Product (Vascular, Non-vascular), By Material (Metallic, Non-metallic), By End-use (Hospitals, Ambulatory Care Centers, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030

Stents Market Growth & Trends

The global stents market is anticipated to reach USD 18.46 billion by 2030 and is anticipated to grow at a CAGR of 3.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is significantly influenced by ongoing technological advancements in medical devices. Innovations such as drug-eluting stents (DES) have transformed the treatment landscape for cardiovascular diseases. These stents are designed to release medication over time, which helps to prevent restenosis, or the re-narrowing of blood vessels after angioplasty. Furthermore, advancements in materials science have led to the development of bioresorbable stents that dissolve over time, reducing long-term complications associated with permanent implants. The integration of advanced imaging techniques and minimally invasive surgical methods also enhances the efficacy and safety of stent placement procedures, thereby driving market growth.

Rising incidence of cardiovascular diseases (CVDs) globally contributes to the expansion of stents market. Factors such as sedentary lifestyles, unhealthy diets, and increasing rates of obesity and diabetes have led to a higher prevalence of conditions like coronary artery disease (CAD). As CVD remains one of the leading causes of morbidity and mortality worldwide, there is a growing demand for effective treatment options, including stenting procedures. This trend is further supported by an aging population that is more susceptible to heart-related ailments, thus propelling the need for interventional cardiology solutions.

Favorable reimbursement policies from healthcare systems encourage hospitals and clinics to adopt newer stenting technologies. This financial support makes these interventions more accessible and incentivizes manufacturers to invest in research and development for next-generation stent products. In June 2024, Royal Philips, a leader in health technology, announced the first implantation of the Duo Venous Stent System. This device, approved for treating symptomatic venous outflow obstruction in chronic venous insufficiency (CVI) patients, received premarket approval from the U.S. FDA.

Stents Market Report Highlights

• Based on product, vascular segment held largest revenue share of 87.3% in 2024 due to the high prevalence of cardiovascular diseases, which necessitate interventions such as stent placements. Advancements in stent technology, including drug-eluting stents that reduce restenosis rates, have further solidified the vascular segment’s position.
• Non-vascular segment is expected to grow at the fastest CAGR over the forecast period owing to its application in various medical conditions beyond cardiovascular issues, such as urology and gastroenterology.
• Based on material, metallic stents segment dominated the segment with a market share of 61.2% in 2024 due to their strength, flexibility, and ability to maintain patency in high-pressure environments. They are particularly effective in vascular applications, where structural integrity is crucial for long-term success.
• Non-metallic stents segment is expected to grow at the fastest CAGR over the forecast period. The non-metallic segment, including biodegradable and polymer-based stents, is gaining traction because they offer advantages such as reduced risk of thrombosis and inflammation.
• Based on end use, hospitals segment held the largest revenue share in 2024 by end use due to their comprehensive infrastructure and advanced medical technology. Hospitals are equipped with specialized facilities and skilled healthcare professionals capable of performing complex procedures that require stent implantation, such as coronary angioplasty.
• Ambulatory care centers (ACS) segment is expected to grow at the fastest CAGR over the forecast period owing to their ability to provide outpatient services at lower costs compared to traditional hospitals. ASCs offer convenience and efficiency, allowing patients to undergo stent procedures without the need for extended hospital stays.
• North America dominated the market in 2024 due to rising incidence of cardiovascular diseases (CVDs). Continuous innovations in stent technology enhance their effectiveness and safety, making them more appealing to healthcare providers and patients alike. Asia Pacific is expected to grow at the fastest CAGR over the forecast period.
• In September 2024, Renata Medical announced the successful implantation of its Minima Growth Stent in a 2-year-old patient at Children’s Hospital Los Angeles, following its recent FDA approval in August. This marks a significant advancement in treating pediatric congenital heart defects, offering a stent that grows with the patient and addresses the limitations of traditional stents.

Please note The report will be delivered in 2-3 business days upon order notification.